Results 321 to 330 of about 26,342,104 (415)

Challenges for the human immune system after leaving Earth. [PDF]

NPJ Microgravity
Marchal S, Choukér A, Bereiter-Hahn J, Kraus A, Grimm D, Krüger M.   +5 more
europepmc   +1 more source

Reconstitution of CXCR3+ CCR6+ Th17.1‐Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Objectives Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple ...
Shu Yang, Tian‐Xiang Zhang, Jia Liu, Zhirui Liu, Lijie Zhu, Yan‐Yan Li, Bin Feng, Moli Fan, Fu‐Dong Shi, Chao Zhang   +9 more
wiley   +1 more source

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors? [PDF]

Biomedicines
Failla CM, Carbone ML, Ramondino C, Bruni E, Orecchia A.   +4 more
europepmc   +1 more source

CSF Tau Is a Biomarker of Hippocampal Injury in Cryptogenic New‐Onset Refractory Status Epilepticus

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cryptogenic new‐onset refractory status epilepticus (cNORSE) is a devastating condition characterized by the de novo onset of status epilepticus with unclear etiology. The identification of relevant early biomarkers in cNORSE is important to elucidate pathophysiology, aid clinical decision‐making, and prognosticate outcomes in cNORSE.
Yihui Goh, Yoonhyuk Jang, Soo Jean Shin, Soo Hyun Ahn, Su Yee Mon, Yoon Hee Shin, Kon Chu, Sang Kun Lee, Soon‐Tae Lee   +8 more
wiley   +1 more source

The functions of immune system-derived miRNAs in cardiovascular diseases. [PDF]

Noncoding RNA Res
Sufianov A, Agaverdiev M, Mashkin A, Ilyasova T.   +3 more
europepmc   +1 more source

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source

Immunosuppressive Drugs in Early Systemic Sclerosis and Prevention of Damage Accrual

Arthritis Care &Research, EarlyView.
Objective Organ damage in patients with systemic sclerosis (SSc) in individual organs such as the lungs may be prevented by receiving immunosuppressive drugs (ISs). A new measure of global organ damage, the Scleroderma Clinical Trials Consortium Damage Index (SCTC‐DI), has allowed us to investigate whether receiving ISs may reduce global organ damage ...
Murray Baron, Mandana Nikpour, Dylan Hansen, Susanna Proudman, Wendy Stevens, on behalf of the Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group, Joanne Sahhar, Nava Ferdowsi, Kathleen Morrisroe, Laura Ross, Gene Siew Ngian, Jennifer Walker, Janet Roddy, Lauren Host, Mohammed Osman, Peter Docherty, Paul Fortin, Marvin Jacob Fritzler, Genevieve Gyger, Alena Ikic, Niall Jones, Elzbieta Kaminska, Maggie Larche, Sophie Ligier, Ada Man, Ariel Masetto, Janet Pope, David Robinson, Tatiana Sofia Rodriguez‐Reyna, Mianbo Wang   +29 more
wiley   +1 more source

Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation. [PDF]

Cell Death Dis
Rossi T, Valgiusti M, Puccetti M, Miserocchi G, Zanoni M, Angeli D, Arienti C, Pace I, Bassi C, Vannini I, Melloni M, Bandini E, Urbini M, Negrini M, Bonafè M, Ferracin M, Gallerani G.   +16 more
europepmc   +1 more source

Pregnancy Outcomes of Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review

Arthritis Care &Research, EarlyView.
Objective Targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy.
Vienna Cheng, Neda Amiri, Vicki Cheng, Ursula Ellis, Jacquelyn J. Cragg, Mark Harrison, Laurie Proulx, Mary A. De Vera   +7 more
wiley   +1 more source

Alzheimer's disease and the immune system: the emerging role of TEMRA cells. [PDF]

Neural Regen Res
Winford ED, Bachstetter AD.
europepmc   +1 more source